Synchrotron X-ray Crystallography in Drug Discovery
We highlight a study conducted by the AstraZeneca team on synchrotron X-ray crystallography in drug discovery (Käck & Sjögren, 2024).
structure-based drug design
-
-
Crystallographic Fragment Screening In Drug Discovery: Background & Advantages
Technical developments have made crystallographic fragment screening the most effective method for screening fragment libraries. Here, we provide a brief overview of the method and its requirements.
-
The Exciting World of Macrocyclic Peptide Drug Structures
Macrocyclic peptide drug structures (often 4 to 24 amino acids) fall between small-molecule drugs and biologics (such as monoclonal antibodies). We discuss the unique features of these structures.
-
Early Drug Discovery Services: Why Do You Need A CRO?
We discuss the the early drug discovery services market and highlight the integrated drug discovery CRO services provided by SARomics Biostructures.
-
DNA-Encoded Library Screening For Drug Discovery
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s unique DNA-encoded library (DEL) screening technology.
-
Protein-Ligand Interactions: Room Temperature or Cryo-Crystallography?
After many years of cryo-crystallography dominance, room-temperature X-ray crystallography using synchrotron radiation has returned. We discuss the application of room-temperature X-ray crystallography in drug design.
-
How to Choose A Library for Screening?
In this third post on structural biology and structure-based drug design we discuss methods and benefits of fragment-based lead discovery
-
The Dusquetide Saga – a Structural Blast From the Past!
A pleasant surprise! A paper describing the interaction of the therapeutic peptide dusquetide with the ZZ domain of the autophagic receptor p62 was published around 12 years after the structure was solved!
-
LundaGUARD – A Consortium For Fighting Infectious Agents
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious agents.
